



Protein- and Subunit-Based Vaccines

Guest Editors:

Dr. Marco Palma

Institute for Globally Distributed
Open Research and Education
(IGDORE), Torrevieja, Spain

Prof. Dr. Jorge Benavide

Tecnologico de Monterrey,
Institute for Obesity Research,
Monterrey, Mexico

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editors

Protein- or subunit-based vaccines comprise whole proteins or portions of them, such as epitopes, that have been specifically chosen for their capacity to stimulate an immune response. Traditional vaccines based on whole-pathogen have been effective in preventing many infectious diseases. However, traditional vaccines have some limitations regarding security issues as many of them need to be produced in high-level biosafety facilities, implying substantial manufacturing costs.

As an alternative, protein- and subunit-based vaccines can be produced using recombinant expression systems, focusing only on the specific portion of the pathogen that triggers the immune response. They often need a substance or component that elicits a more potent humoral or cellular immune response. Different components have been used as adjuvants, and other approaches have been applied to deliver and present proteins and epitopes to the immune system.

This Special Issue focuses on protein- and subunit-based vaccines, including preclinical and clinical studies, alternative delivery and display approaches, formulation optimization, and production strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com